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Abstract Studies on the occurrence of gout show a large
range in estimates. However, a clear insight into the factors
responsible for this variation in estimates is lacking.
Therefore, our aim was to review the literature on the
prevalence and incidence of gout systematically and to
obtain insight into the degree of and factors contributing to
the heterogeneity. We searched MEDLINE, EMBASE, and
Web of Science (January 1962 to July 2012) to identify
primary studies on the prevalence and incidence of gout in
the general population. Data were extracted by two persons
on sources of clinical heterogeneity, methodological het-
erogeneity, and variation in outcome reporting. Meta-ana-
lysis and meta-regression analysis were performed for the
prevalence of gout. Of 1,466 articles screened, 77 articles
were included, of which 71 reported the prevalence and 12
the incidence of gout. The pooled prevalence (67 studies;
N = 12,226,425) based on a random effects model was
0.6 % (95 % CI 0.4; 0.7), however there was a high level
of heterogeneity (I2 = 99.9 %). Results from a mixed-
effects meta-regression model indicated that age
(p = 0.019), sex (p \ 0.001), continent (p \ 0.001),
response rate (p = 0.016), consistency in data collection
(p = 0.002), and case definition (p \ 0.001) were signifi-
cantly associated with gout prevalence and jointly
accounted for 88.7 % of the heterogeneity. The incidence
in the total population ranged from 0.06 to 2.68 per 1,000
person-years. In conclusion, gout is a common disease and
the large variation in the prevalence data on gout is
explained by sex, continent on which the study was per-
formed, and the case definition of gout.
Keywords Gout  Prevalence  Incidence  Systematic
review  Meta-regression
Introduction
Gout is an inflammatory arthritis which has been associated
with the metabolic syndrome, hypertension, kidney
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disease, and cardiovascular disease [1]. Partially due to the
associated co-morbidity, gout has a substantial impact on
an patient’s health-related quality of life [2] and may be a
major health issue in affluent countries [3]. Studies on the
prevalence and incidence of gout in the general population
show a large range in estimates and an increase in these
estimates has often been suggested [4]. However, a clear
insight into the factors contributing to this variation in
estimates is lacking. Meta-analysis and meta-regression are
helpful techniques that may shed light on the reasons for
the heterogeneity in the findings.
In systematic reviews, two major types of heterogeneity
can be distinguished, i.e. clinical and methodological het-
erogeneity. Clinical heterogeneity refers to differences in
patient characteristics or treatment regimen, while meth-
odological heterogeneity refers to variation in study design,
outcome measures, and the duration of follow up. Several
sources of heterogeneity emerged from previous studies on
the prevalence and incidence of gout, such as age, sex,
geographic region (representing ethnic background and
susceptibility to gout) [5], and case definition [6–9]. In
contrast to these studies, meta-regression can assess and
quantify the effect of these factors on the occurrence of
gout simultaneously.
The aim of the present study was to review literature on
the prevalence and incidence of gout systematically and to
perform a meta-analysis including meta-regression analysis
to obtain insight into the degree of and factors contributing
to the heterogeneity.
Materials and methods
Data sources and searches
MEDLINE, EMBASE, and Web of Science were searched
for primary studies on the prevalence and/or incidence of
gout using the free text- and MeSH-search term ‘‘gout’’
with subheading ‘‘epidemiology’’, and the search term
‘‘gout’’ in combination with ‘‘epidemiology’’, ‘‘preva-
lence’’, and ‘‘incidence’’. Replacing the search term ‘‘gout’’
by the keywords ‘‘crystal arthritis’’ or ‘‘crystal arthropa-
thy’’ did not lead to additional titles.
The search was limited to articles published in English,
German, French, Spanish, or Dutch. Letters, comments,
and editorial citations were excluded by adding the search
term: NOT ‘‘letter’’ [Publication Type] NOT ‘‘comment’’
[Publication Type] NOT ‘‘editorial’’ [Publication Type].
The search was executed on 22 February 2010 and was
last updated on 1 July 2012. References were imported in
Endnote and duplicates were removed. Finally, hand
search of bibliographies of relevant articles was
performed.
Study selection
Two reviewers (JW, SvL) independently screened titles
and (if available) the corresponding abstracts. Studies were
included if; (1) the aim of the study was to estimate the
prevalence and/or incidence of gout; (2) primary data,
derived from a new or original research study, were
reported; (3) the general population was the target. Any
disagreement was resolved after consensus between the
two reviewers (JW, SvL). Full-text articles of the selected
titles were accessed via PUBMED or were requested from
the corresponding authors, after which a full-text review
was performed by the first reviewer (JW).
Data extraction
Data were extracted by two independent reviewers (JW,
KT). In case of disagreement, a third reviewer (AB) was
consulted and consensus reached. In addition to study
identification, data extraction comprised sources of clinical
heterogeneity (mean age of the sample, male/female dis-
tribution, country, setting), and sources of methodological
heterogeneity (year in which data collection began, sam-
pling frame to recruit study population, sampling method,
exclusion criteria, response rate, representativeness of
study population for the general population, case definition
for gout, duration of follow up in case of an incidence
study, consistency in case finding and case definition
throughout the study). Finally variables related to outcome
reporting were extracted (figures on prevalence and/or
incidence including its numerator and denominator, confi-
dence intervals, measure of prevalence and/or incidence).
Data synthesis and analysis
Variables in meta-regression analyses
With regard to clinical heterogeneity, the percentage of
males and the mean age of the sample were included in the
analyses as continuous variables. Continent of study exe-
cution was subdivided into seven categories: Europe, North
America, South America, Africa, Asia, Oceania, and
‘‘indigenous people’’ (composed of Maori, Aboriginals and
Inuit). Indigenous people were analysed as a separate cat-
egory since these individuals represent a unique population
in which high gout prevalences are generally found, partly
due to a marked genetic predisposition for hyperuricaemia
[6, 10]. The setting was subdivided into urban, rural, or a
combination of both.
With respect to methodological heterogeneity, year in
which data collection began (or publication year if not
reported) was handled as a continuous variable. The fol-
lowing four variables were scored dichotomously: response
20 J. M. A. Wijnands et al.
123
rate was deemed appropriate if either 75 % or more of the
sampled subjects participated, or if participation was\75 %
but data analysis included a non-responder analysis showing
no difference in participants’ characteristics between
responders and non-responders; the sampling method was
appropriate if a random selection was used; consistency in
data collection was appropriate if the approach was sim-
ilar across all participants; and representativeness of the
study population if the methods used to select the study
population were deemed appropriate to obtain a studied
sample truly representative of the general population. The
following two variables were categorized. The sampling
frame was categorized into census list, household register,
convenience sample, general practitioner database, hos-
pital database, list of specific group of subjects (employees
of a company), and geographic sampling. The case defini-
tion of gout was categorized into seven categories. The first
two categories comprised a self-reported diagnosis of gout
or self-reported symptoms suggestive of gout recorded by
a questionnaire or an interview. Categories 3 and 4
involved a 2-step case definition in which a self-reported
screening question (as in categories 1 and 2) was followed
by a confirmation of cases based on additional clinical
criteria, physical exam, or ICD codes. In case health
professionals examined all participants the case definition
was coded with category 5. Finally, ICD codes/free text
search in general practitioner medical records or hospital
medical records were coded as categories 6 and 7,
respectively.
For outcome reporting, the measure of prevalence was
dichotomized as lifetime or period, and the measure of
incidence as proportion or incidence rate.
Prevalence studies
Where possible, data from individual articles were subdi-
vided into independent samples to allow for separate
results based on sex, ethnic group, setting, or location (e.g.
instead of computing a single prevalence rate for an article,
prevalence rates for the male and female subsamples were
included in the meta-analysis). To avoid statistical depen-
dence in the estimates, if an article reported the prevalence
of a specific population over time, only the most recent
estimation was used. The prevalence for each sample was
calculated using raw data (i.e. number of cases divided by
the sample size). In case of a missing numerator, the
number of cases was back-calculated from the reported
prevalence rate (%) and the sample size.
Prevalence rates were transformed with the logit (log
odds) transformation before further analysis [11, 12]. The
sampling distribution of a logit transformed rate is better
approximated by a normal distribution, especially when the
true prevalence rate is close to zero. For samples with zero
cases, we used the standard bias/continuity correction of
adding  to the number of cases and non-cases before
computing the logit transformed rates.
To estimate the pooled prevalence, the transformed
prevalence rates were combined in a meta-analysis using a
random-effects model. The pooled result and the corre-
sponding confidence interval bounds were then back-
transformed to yield an estimate of the average prevalence
rate. Based on the results from the random-effects model, a
95 % prediction interval was calculated, which provides an
estimate of the range where future prevalences are expec-
ted to fall in 95 % of the individual study settings [13]. The
amount of heterogeneity between studies was estimated
using the empirical Bayes estimator and reported in terms
of the I2-statistic [14].
A sensitivity analysis, excluding studies with ‘‘low study
quality’’, was not performed because of scientific objec-
tions to computing a quality rating score or weighting of
quality items [15]. Instead, the contribution of methodo-
logical and clinical aspects of diversity (including aspects
of quality) to the heterogeneity was explored by perform-
ing meta-regression analyses using mixed-effects models
[16]. Univariable and multivariable models were fitted,
using the empirical Bayes method to estimate the amount
of residual heterogeneity [14], and model coefficients were
tested using the Knapp and Hartung method [17]. Pairwise
comparisons were obtained for categorical variables with
p values adjusted by Holm’s method [18]. We estimated
the amount of heterogeneity accounted for by moderators
by computing the proportional reduction in the amount of
heterogeneity when the moderators are included in the
model [16].
Sensitivity analyses were performed using two alterna-
tive modeling approaches for the multivariable meta-
regression analysis, i.e. using a mixed-effects logistic
regression model with random effects per observed out-
come and a beta-binomial model with logit link function.
All analyses were performed with R using the packages
metafor [19], lme4 [20], and VGAM [21].
Incidence studies
Due to the small number of articles on the incidence of gout
we chose to describe these studies and to inspect the data
carefully rather than conducting meta-regression analyses.
Results
Study selection
The literature search provided a total of 2,126 hits
(PubMed: n = 1,018, EMBASE: n = 664, Web of
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Science: n = 444). After removing duplicates, 1,466
titles, the majority including abstracts, were screened for
eligibility, resulting in 86 candidate titles. For 10 studies
no full text could be retrieved despite the use of interli-
brary loan services and a search for contact details of first
authors.
After full text review 12 articles did not meet the
inclusion criteria (3 titles referred to congress abstracts
only, 3 did not provide primary data, and in 6 the target
was not the general population). Five further articles were
excluded because they reported on the same study popu-
lation and the paper providing the most complete data on
clinical and methodological heterogeneity was considered.
The hand search of bibliographies of relevant articles
resulted in an additional 7 articles and 11 new articles were
included after the last update (1 July 2012). Finally, 77
articles were included, of which 71 reported prevalence and
12 incidence (Fig. 1).
Prevalence
Study characteristics
In the 71 articles [22–92], 172 independent samples were
identified (Online Resource 1). Table 1 presents charac-
teristics of these samples. Studies were carried out between
1950 and 2012. The total number of individuals in these 71
articles was unknown as denominators were not reported in
all studies. Approximately 50.9 % (range 0–100 %) of the
total population was male with an average age of *45
(31–79) years. Studies were mainly conducted in Asia (61
out of 172, 35.5 %) and Europe (48 out of 172, 27.9 %).
Fifty-five (38.2 % of 144) studies used a census and 37
(25.7 % of 144) a general practitioner database for sam-
pling individuals. The case definition most frequently used
was the 2-step approach where self-reported symptoms was
followed by further confirmation (52 out of 172, 30.2 %).
Full-text articles assessed 
for eligibility 
(n=76)
Records excluded 
(n=1380)
No full text (n=10)
Studies included in 
qualitative synthesis 
(n=77)
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n=67)
Articles excluded;
Not eligible (n=12)
Same population (n=5)
Reference search 
(n=7)
New articles since search 
(n=11)
Records screened 
(n=1466)
References identified through 
database searching 
(n=2126)
Duplicates removed 
(n=660)
Fig. 1 Selection of studies for the systematic review of the prevalence and incidence of gout
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Meta-analysis
The meta-analysis was conducted based on 165 (95.9 %)
samples extracted from 67 studies where the raw preva-
lence was available or could be computed. In total, the 165
samples comprised 237,464 cases and a sample size of
12,226,425 individuals. The observed prevalence ranged
from 0 to 26.2 % with an unweighted mean of 1.6 %
(SD = 3.3 %; median = 0.3 %). Thirty-two samples
(19.4 %) reported a prevalence of 0 %. The pooled (back-
transformed) estimated average prevalence based on the
meta-analysis was 0.6 % (95 % CI 0.4; 0.7). The 95 %
prediction interval was 0.03–11.16 %. Note that 10 sam-
ples with sample sizes larger than 100,000 comprised
94.2 % of the total sample size. The I2 statistic indicated a
very high level of heterogeneity (99.9 %).
Table 1 Characteristics of 71 studies reporting the prevalence of gout that were considered as sources of heterogeneity
Clinical heterogeneity Methodological heterogeneity Outcome reporting
Mean age (n = 129)
Range 31–79
Median 43.0
Mean 44.4
% Males (n = 165)
Range 0–100
Median 48.8
Mean 50.9
Continent (n = 172):
1. Europe: n = 48
2. North America: n = 16
3. South America: n = 9
4. Africa: n = 6
5. Asia: n = 61
6. Oceania: n = 22
7. Indigenous people: n = 10 (composed of Maori,
Aboriginals and Eskimos)
Setting (n = 159)
1. Rural: n = 37
2. Urban: n = 54
3. Combination urban en rural: n = 68
Start data collection (n = 172)
Range 1950–2012
Median 1994
Mean 1990
Response rate (n = 172)
1. Adequate: n = 119a
2. Non-adequate: n = 53
Sampling method (n = 172)
1. Random: n = 128
2. Non-random: n = 44
Consistency data collection (n = 172)
1. Approach was similar across all participants:
n = 157
2. Approach was not similar across all participants:
n = 15
Sampling frame (n = 144):
1. Census: n = 55
2. Household register: n = 27
3. Convenience sample: n = 8
4. General practitioner database: n = 37
5. Hospital database: n = 4
6. List of specific group of subjects: n = 5 (e.g.
employees of a company)
7. Geographic sampling: n = 8
Representation general population (n = 172)
1. Yes: n = 26
2. No: n = 146
Case definition (n = 172)
1. Self-reported diagnosis: n = 18
2. Self-reported symptoms: n = 11
3. 2-step approach diagnosis: n = 10
4. 2-step approach symptoms: n = 52
5. Diagnose health professional: n = 46
6. Medial record general practitioner: n = 31
7. Medical record hospital: n = 4
Measure of prevalence
(n = 166)
1. Life time prevalence
(n = 141)
2. Period prevalence
(n = 25)
a Response rate C75 or \75 % but data analysis included a non-responder analysis
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Univariable meta-regression analyses
Mean age, sex, continent, and case definition were signif-
icantly associated with the prevalence, accounting respec-
tively for 8.8, 20.7, 31.2, and 33.6 % of the heterogeneity
(Table 2). Start of data collection was not significantly
associated with the prevalence of gout (p = 0.719). Pair-
wise comparison showed that in indigenous people (Maori,
Aboriginals, Inuit) and Oceania higher prevalences were
found compared to Europe (p = 0.004; p = 0.013), South
America (p = 0.002; p = 0.009), and Asia (p \ 0.001;
p \ 0.001) (Fig. 2 and Online Resource 2). Europe and
North America reported higher prevalences in comparison
to Asia (p = 0.022; p \ 0.001). Within ‘case definition’,
self-reported approaches resulted in higher estimates of
prevalences compared with: a 2-step approach using gout
Table 2 Univariable meta-regression analyses on the prevalence of gout
Moderator Univariable analyses
b SE OR (95 %CI) p value R2
Clinical heterogeneity
Mean age 0.0625 0.0190 1.06 (1.03; 1.11) 0.001 8.8
% male 0.0153 0.0026 1.02 (1.01; 1.02) \0.001 20.7
Continent \0.001 31.2
Reference = Europe North America 0.9253 0.3926 2.52 (1.16; 5.48) 0.020
F(df = 6, df = 158) = 10.8 South America -0.7192 0.5250 0.49 (0.17; 1.37) 0.173
Africa -0.2869 0.7298 0.75 (0.18; 3.17) 0.695
Asia -0.9152 0.2895 0.40 (0.23; 0.71) 0.002
Oceania 1.2495 0.3741 3.49 (1.67; 7.30) 0.001
Indigenous people 1.8119 0.4881 6.12 (2.33; 16.05) \0.001
Setting 0.641 0.0
Reference = Rural Urban 0.1258 0.3874 1.13 (0.53; 2.44) 0.746
F(df = 2, df = 149) = 0.4 Combination urban and rural 0.3271 0.3666 1.39 (0.67; 2.86) 0.374
Methodological heterogeneity
Start data collection -0.0032 0.0088 1.00 (0.98; 1.01) 0.719 0.0
Response rate 0.1881 0.2903 1.21 (0.68; 2.14) 0.518 0.0
Sampling method 0.0644 0.3062 1.07 (0.58; 1.95) 0.834 0.0
Consistency data collection -0.5815 0.5175 0.56 (0.20; 1.55) 0.263 0.2
Sampling framea 0.075 4.9
Reference = Census Household register 0.0007 0.4071 1.00 (0.45; 2.24) 0.999
F(df = 6, df = 130) = 2.0 Convenience sample 1.5200 0.6300 4.57 (1.31; 15.90) 0.017
General practitioner database 0.2113 0.3602 1.24 (0.61; 2.52) 0.558
Hospital database 0.7081 0.8446 2.03 (0.38; 10.79) 0.403
List of specific group of subjects -0.7264 0.7809 0.48 (0.10; 2.27) 0.354
Geographic sampling -1.1355 0.6900 0.32 (0.08; 1.26) 0.102
Representativeness study population -0.3873 0.3764 0.68 (0.32; 1.43) 0.305 0.0
Case definition \0.001 33.6
Reference = Self-reported diagnosis Self-reported symptoms -0.3202 0.5300 0.73 (0.25; 2.07) 0.547
F(df = 6, df = 158) = 11.9 2-step approach diagnosis -0.9793 0.5500 0.38 (0.13; 1.11) 0.077
2-step approach symptoms -2.8317 0.3896 0.06 (0.03; 0.13) \0.001
Diagnose health professional -1.7812 0.4016 0.17 (0.08; 0.37) \0.001
Medical record general
practitioner
-1.8842 0.4091 0.15 (0.07; 0.34) \0.001
Medical record hospital -1.1179 0.7536 0.33 (0.07; 1.45) 0.140
Outcome reporting
Measure of prevalence
Reference = Life-time prevalence Period prevalence 0.3056 0.3863 1.36 (0.63; 2.91) 0.430 0.0
SE standard error, R2 = the amount of heterogeneity accounted for by the predictor in %
24 J. M. A. Wijnands et al.
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symptoms as a screening question; diagnoses by a health
professional; or ICD code/free text in medical records of
general practitioners (range p values \0.001–0.029). The
2-step approach based on self-reported diagnosis, diagnosis
by a health professional, and ICD code in medical records
of general practitioners resulted in a significantly higher
prevalence than the 2-step approach based on self-reported
symptoms (p = 0.002; p = 0.011; p = 0.039). Finally,
within the sampling frame, a convenience sample frame
estimates higher prevalence compared with geographic
sampling (p = 0.048).
Multivariable meta-regression analysis
Table 3 shows the results of the multivariable analysis.
Due to collinearity between case definition and sampling
frame, the latter was not included in the total model. The
multivariable analysis included 109 (63.4 %) samples,
comprising a reduced total sample size of 3,813,476 indi-
viduals from 47 studies due to missing data on the sources
of clinical and methodological heterogeneity. The variables
age (p = 0.019), sex (p \ 0.001), continent (p \ 0.001),
case definition (p \ 0.001), response rate (p = 0.016), and
consistency in data collection (p = 0.002) were signifi-
cantly associated with gout prevalence (Table 3). Pairwise
comparison showed that in indigenous people significantly
higher prevalence rates were reported compared to all
continents (all p \ 0.01), except for Africa (supplementary
material 2). Note that results on Africa are based on a small
number of samples. Studies performed in Oceania and
North America estimated significantly higher gout preva-
lences compared to: Asia (p \ 0.001; p \ 0.001); South
America (p = 0.001; p = 0.003); and Europe (p \ 0.001;
p = 0.002). Within ‘case definition’, self-reported symp-
toms and the 2-step approach based on self-reported
diagnosis provided significantly higher prevalences in
comparison to a 2-step approach based on self-reported
symptoms (p = 0.001; p = 0.001) or a diagnosis by a
health professional (p \ 0.001; p = 0.002).
The multivariable model accounted for 88.7 % of the
variance. The predicted prevalences based on this model
closely corresponded with the observed prevalences in the
individuals studies (Fig. 3). Therefore, the prevalence for
any given population may be estimated based on the
multivariable model as shown in Table 3. For example, a
study performed in 2012 in an Asian population (combin-
ing both urban and rural area) with a mean age of
44.4 years and 50.9 % males, in which gout is classified
using a 2-step approach based on symptoms (representing
the population with characteristics that are most frequently
reported on), would provide an estimated life time preva-
lence of 0.03 % (95 %CI 0.01; 0.09). In contrast, a study
performed in 2012 in North America with a similar age and
sex distribution, but with a gout diagnosis based on self-
reported symptoms, would provide an estimated life time
prevalence of 1.37 % (95 %CI 0.43; 4.24). A study with
similar characteristics as the latter, but with a 20 years
older population (mean age = 64.4 yrs), would result in an
estimated prevalence of 2.95 % (95 %CI 0.94; 8.86).
Sensitivity analyses
Sensitivity analyses were performed using two alternative
modeling approaches for the multivariable regression ana-
lysis: (1) using a mixed-effects logistic regression model with
random effects per observed outcome and (2) a beta-binomial
model with logit link function. The conclusions with respect to
the relevant predictors remained largely unchanged. How-
ever, using the first alternative method, the prevalence in Asia
was no longer different from the one in Europe, whereas the
case definition 2-step approach based on self-reported diag-
nosis was now significantly different from self-reported
diagnosis. Using the beta-binomial model, the case definitions
self-reported symptoms and the 2-step approach based on self-
reported diagnosis were significantly different from self-
reported diagnosis, but the 2-step approach based on self-
reported symptoms and a diagnosis by a health professional
were no longer different from each other.
Incidence
Study characteristics
Incidence rates were reported in 12 articles [34, 44, 50, 54,
67, 84, 93–98]. Studies were carried out between 1950 and
2012. Due to incomplete method description and missing
numerators, denominators, or the number of subjects in the
study, the measure of incidence (incidence proportion or
incidence rate) was not always clear.
Study results
By scrutinizing extracted data, we observed an influence of
duration of follow-up of the cohort on the reported inci-
dence (Table 4). Within the studies with a follow-up
B2 years or in studies reporting annual rates, incidences
ranged between 0.06/1,000 and 1.80/1,000, with higher
incidences in men (0.12/1,000 to 1.98/1,000) than in
women (0.0/1,000 to 0.74/1,000). Within studies with a
longer follow-up ([2 years) an incidence of 2.68/1,000
person-years was reported, with incidences varying
between 2.8/1,000 to 4.42/1,000 in men and 1.32/1,000 to
1.4/1,000 in women. Follow-up periods ranged from 7 to
52 years. In a study performed in Maori with 11 year fol-
low-up, an incidence of 103/1,000 in men and 43/1,000 in
women was reported [34].
Determinants of the prevalence of gout in the general population 25
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Note that some studies calculated incidence rates or
proportions using an unconventional method, that is, by
dividing new cases by the number of individuals re-
examined after 11 years [34]; by using a denominator
based on only the re-examined individuals with hyperuri-
cemia [97]; or by dividing new cases (2002–2003) by
census data of 2001, not excluding prevalent cases [54].
Six articles studied the incidence of gout over time. Four
did not find evidence for an increasing or decreasing trend
in incidence [50, 67, 84, 98]. However, Currie et al. [44]
noted a significant difference between the incidence in
b
Table 3 Multivariable meta-regression analysis on the prevalence of gout
Moderator Multivariable analysisa
b SE OR (95 %CI) p value
Clinical heterogeneity
Mean age 0.0393 0.0164 1.04 (1.01; 1.07) 0.019
% male 0.0168 0.0016 1.02 (1.01; 1.02) \0.001
Continent \0.001
Reference = Europe North America 1.3281 0.3544 1.87 (1.87; 7.63) \0.001
F(df = 6, df = 86) = 22.2 South America -0.3626 0.4541 0.70 (0.28; 1.72) 0.427
Africa 2.726 1.1326 15.27 (1.61; 145.05)c 0.018
Asia -0.7383 0.3306 0.48 (0.24; 0.92) 0.029
Oceania 1.5363 0.3636 4.65 (2.26; 9.58) \0.001
Indigenous people 2.8163 0.4083 16.7 (7.42; 37.63) \0.001
Setting 0.250
Reference = rural Urban 0.3840 0.2460 1.47 (0.90; 2.39) 0.122
F(df = 2, df = 86) = 1.4 Combination urban
and rural
0.1722 0.3148 1.19 (0.64; 2.22) 0.586
Methodological heterogeneity
Start data collection -0.0007 0.0082 1.00 (0.98; 1.02) 0.937
Response rate 0.6193 0.2523 1.86 (1.13; 3.07) 0.016
Sampling method -0.2410 0.2310 0.79 (0.50; 1.24) 0.300
Consistency data collection -1.5058 0.4742 0.22 (0.09; 0.57) 0.002
Representativeness study
population
-0.1987 0.3257 0.82 (0.43; 1.57) 0.543
Case definition \0.001
Reference = self-reported diagnosis Self-reported symptoms 0.7527 0.4396 2.12 (0.89; 5.09) 0.090
F(df = 6, df = 86) = 6.0 2-step approach diagnosis 0.8079 0.4985 2.24 (0.83; 6.04) 0.109
2-step approach symptoms -0.8786 0.3987 0.42 (0.19; 0.92) 0.030
Diagnose health
professional
-0.8818 0.3979 0.41 (0.19; 0.91) 0.029
Medical record general
practitioner
-0.3065 0.4548 0.74 (0.30; 1.82) 0.502
Medical record hospital -0.1233 0.7535 0.88 (0.20; 3.95) 0.870
Outcome reporting
Measure of prevalence
Reference = life-time prevalence Period prevalence 0.1449 0.2964 1.16 (0.64; 2.08) 0.626
a Due to collinearity between case definition and sampling frame, the latter was excluded from multivariable analysis
b Intercept of multivariable model: b = -6.4984; SE = 16.2324
c The small number of samples within the level ‘‘Africa’’ resulted in the large 95 %CI
SE standard error
Fig. 2 Scatterplots for the continuous predictors and boxplots for the
categorical predictors with the y-axis corresponding to the logit
transformed prevalence rates plotted proportional to the sample sizes.
Continent (1 Europe, 2 North America, 3 South America, 4 Africa, 5
Asia, 6 Oceania, 7 Indigenous people). Case definition (1 Self-
reported diagnosis, 2 Self-reported symptoms, 3 2-step approach
diagnosis, 4 2-step approach symptoms, 5 Diagnose health profes-
sional, 6 Medial record GP, 7 Medical record hospital). Setting (1
rural, 2 urban, 3 combination). Sampling frame (1 Census, 2
Household register, 3 Convenience sample, 4 General practitioner
database, 5 Hospital database, 6 List of specific group of subjects, 7
Geographic sampling). Measure of prevalence (1 lifetime prevalence,
2 period prevalence)
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1971–1972 (0.29/1,000) and 1974–1975 (0.35/1,000) in
England, but not in Scotland, Wales, and Great Britain as a
whole. Arromdee et al. [93] reported that the age and sex
adjusted incidence for all gout did not significantly increase
(p = 0.10) during a 20-year interval, but found a twofold
increase in incidence of primary gout only (subjects not on
thiazide or diuretics).
Discussion
This study was the first to assess the determinants of the
worldwide prevalence of gout in the general population in a
systematic manner. Our results showed a pooled preva-
lence of 0.6 % (95 % CI 0.4; 0.7) across 67 articles.
However, the prevalence estimates were extremely heter-
ogeneous. Therefore, the pooled prevalence should be
interpreted with caution. Our multivariable model
explained 88.7 % of the heterogeneity and showed an
independent influence of age, sex, continent of study exe-
cution, consistency in data collection, response rate, but
also case definition. In addition, we found that crude
incidence rates of gout varied between 0.06/1,000 and 2.68/
1,000 across 12 articles.
The previously reported lower prevalence of gout in
females and higher prevalence in Oceania [87, 99], North
America [5], and among indigenous people (Maori, Ab-
originals and Inuit) [68, 87] was confirmed in the present
study. A higher prevalence in North America has been
attributed to the presence of varying ethnic groups on this
continent, including Filipinos and African Americans with
high gout prevalences ascribed to the shift from a low-
purine diet to a high-purine Western diet in case of
immigrants [100] and higher rates of hypertension [101].
Case definition accounted, in the univariable analysis,
for 33.6 % of the heterogeneity. A 2-step approach based
on diagnosis and self-reported approaches to define gout
resulted in the highest estimates of the prevalence of gout.
While a previous study suggested that self-report of phy-
sician-diagnosed gout is an adequate proxy of the actual
prevalence [102], we were not able to distinguish this
specific self-reported diagnosis from a simple self-reported
diagnosis method due to small subsamples. Note that the
2-step approaches were most often used and therefore
could have influenced the pooled prevalence.
Because of the limited number of incidence studies a
meta-analysis was not possible. Surprisingly, statistical
approaches to calculate incidence rates were imprecise and
often the exact numerator and denominator were not
reported. When incidence rates are assessed over a long
time frame, it is assumed that the incidence remains con-
stant during the period of study. However, when assessing
a closed cohort, gout incidence will increase with
increasing age. This is probably why we found that studies
with a long follow-up reported higher incidence rates in
comparison to studies reporting an annual incidence.
Among the incidence studies six articles reported inci-
dences across time, of which only two found an increase.
Also, our meta-regression analysis of the prevalence rate
did not show a significant influence of year of study exe-
cution. However, in case a study reported prevalences over
time, only the most recent estimation was considered.
Nevertheless, only two of the four studies that compared
annual prevalence rates for different time points directly
[43, 50, 84, 90] reported the increase to be significant [43,
90]. Based on our results, we suggest that there is insuffi-
cient evidence for a time trend in the worldwide prevalence
and incidence of gout. However, we acknowledge that our
finding may represent the absence of evidence, rather than
evidence of absence.
Some limitations to this study need to be considered.
First, we cannot exclude possible language bias and
availability bias in study inclusion as we limited our search
to five languages and published articles. Second, due to
unavailability of some data from the primary papers, we
had to exclude four articles from the meta-analyses. Third,
coding the different aspects of clinical and methodological
heterogeneity entails some subjectivity, however, coding
was independently performed by two reviewers and dis-
agreement resolved by consensus. Fourth, we used mixed-
effects logistic regression model for the meta-regression
analysis which may have influenced our results. However,
sensitivity analyses showed that the impact of the used
Fig. 3 Scatterplot for the predicted prevalence based on the multi-
variable model and the observed prevalence, both on the logit scale
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method was rather small. Finally, associations of the gout
prevalence with population averages, such as age and sex,
across studies may not reflect findings within studies.
In conclusion, the results of this systematic review show
that gout is a common disease. A large part of the heter-
ogeneity between studies on the prevalence of gout can be
explained by sources of clinical heterogeneity, such as the
world region in which the study was performed, and the
percentage of males in the study population, but also by the
case definition of gout. Researchers should carefully for-
mulate their case definition to facilitate comparison
between studies. In addition, more research is needed to
support the possible time trend towards increasing preva-
lence or incidence of gout in the general population.
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